23 results on '"Ramos-Suzarte, Mayra"'
Search Results
2. Nimotuzumab for COVID-19: case series
3. Semimechanistic Model to Characterize Nonlinear Pharmacokinetics of Nimotuzumab in Patients With Advanced Breast Cancer
4. Biomarkers in Lung Cancer: Integration with Radiogenomics Data
5. Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF® Therapeutic Vaccine
6. Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease
7. Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
8. Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease
9. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
10. PHARMACOKINETICS EVALUATION OF NIMOTUZUMAB IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
11. Immunotrans-arterial Chemoembolization (ITACE) in hepatocellular carcinoma patients treated with anti-EGFR MAb nimotuzumab plus adriamicin. Phase I Clinical Trials, Final Results
12. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
13. Biomarkers in Lung Cancer: Integration with Radiogenomics Data
14. Immunotrans-Arterial Chemoembolization (ITACE) in Hepatocellular Carcinoma Patients Treated with anti-EGFR Mab Nimotuzumab Plus Adriamycin. Phase I Clinical Trial, Final Results
15. Tumor Expression of the Carcinoembryonic Antigen Correlates with High Mitotic Activity and Cell Pleomorphism Index in Lung Carcinoma
16. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
17. Mejoras en el acceso a la información de los ensayos clínicos
18. Diagnostic efficacy and safety of99mTc-Labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: Final report clinical trial phase I/II
19. 99mTc-Labeled Antihuman Epidermal Growth Factor Receptor Antibody in Patients with Tumors of Epithelial Origin: Part III. Clinical Trials Safety and Diagnostic Efficacy.
20. Diagnostic efficacy and safety of 99mTc-Labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: Final report clinical trial phase I/II
21. PD-0022IMMUNOTRANS-ARTERIAL CHEMOEMBOLIZATION (ITACE) IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ANTI-EGFR MAB NIMOTUZUMAB PLUS ADRIAMYCIN. PHASE I CLINICAL TRIAL, FINAL RESULTS.
22. Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease.
23. Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.